Investors Overview

Overview

Alvotech is a global biotech company focused solely on the development and manufacture of biosimilar medicines for patients worldwide. Alvotech seeks to be a global leader in the biosimilar space by delivering high quality, cost-effective products and services, enabled by a fully integrated approach and broad in-house capabilities. Alvotech’s current pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer.




Data Provided by Refinitiv. Minimum 15 minutes delayed.

News Releases

23 Feb '24
SIMLANDI is t he first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S . SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeab le exclusivity in
24 Jan '24
Attached is a filing with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons. Alvotech Investor Relations Benedikt Stefansson, Senior Director alvotech.ir@alvotech.com Attachment Managers Transaction-CSSF Form -

Recent Events